Recommended For You
Recommendations are based off of your interests located in your profile.
Intro to Hematopoietic Cell TransplantationContains 1 Component(s)
This webinar is designed to provide participants an introduction and overview of hematopoietic cell transplantation (HCT). Topics during the presentation include: historical overview of hematopoietic cell transplantation (HCT); review of sources of hematopoietic stem cells utilized in HCT and their associated advantages and disadvantages; summary of the HCT process, including the evaluation of a potential patients, the execution of the HCT procedure itself and associated toxicities and complications; and list of important resources to aid healthcare professionals caring for HCT patients.
CAR-T Slide DeckContains 1 Component(s)
This comprehensive slide library was developed by a group of clinicians that have been working together to develop ongoing educational initiatives about CAR T therapy since 2017. The library covers several topics including: why CAR-T therapy, how CAR-T fits into the world of immuno-oncology, patient management, and institutional considerations.
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host DiseaseContains 1 Component(s)
This article outlining ASTCT Recommendations on First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease was published in 2012.
Oral ManifestationsContains 1 Component(s)
ASTCT offers its members the information, tools and forms they need to stay informed and involved in efforts to develop more effective treatments for chronic graft-versus-host disease (chronic GVHD) an urgent unmet clinical need and the most frequent complication after HCT. This presentation is by Mark M. Schubert, DDS, MSD, Fred Hutchinson Cancer Research Center, after the 2014 Consesn Conference on GVHD.
ASTCT Consensus Grading for CAR-TContains 1 Component(s)
This webinar from October 2019 disccuses the new definitions and grading for CRS and neurotoxicity that more accurately categorize the severity of these toxicities. CAR T cell therapy is considered one of the most promising new treatments for patients battling relapsed and refractory leukemia, lymphoma and other forms of cancer. The assessment and grading of CRS and ICANS have varied considerably across clinical trials, academic studies, and commercial products, which has made it difficult to compare the safety and measure toxicity across all of these settings. This also has hindered the ability of researchers to develop the best strategies to manage these toxicities.